Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
P Vermersch, A Czlonkowska… - Multiple Sclerosis …, 2014 - journals.sagepub.com
Background: In previous studies, teriflunomide significantly reduced the annualised relapse
rate (ARR) and disability progression. Objective: This phase 3, rater-blinded study
(NCT00883337) compared teriflunomide with interferon-beta-1a (IFNβ-1a). Methods:
Patients with relapsing multiple sclerosis were randomised (1: 1: 1) to oral teriflunomide 7-or
14mg, or subcutaneous IFNβ-1a 44µg. The primary composite endpoint was time to failure,
defined as first occurrence of confirmed relapse or permanent treatment discontinuation for …
rate (ARR) and disability progression. Objective: This phase 3, rater-blinded study
(NCT00883337) compared teriflunomide with interferon-beta-1a (IFNβ-1a). Methods:
Patients with relapsing multiple sclerosis were randomised (1: 1: 1) to oral teriflunomide 7-or
14mg, or subcutaneous IFNβ-1a 44µg. The primary composite endpoint was time to failure,
defined as first occurrence of confirmed relapse or permanent treatment discontinuation for …
Teriflunomide versus subcutaneous interferon beta-1 a in patients with relapsing multiple sclerosis: a randomised, controlled Phase 3 trial.
C Warnkes - Current Medical Literature: Multiple Sclerosis, 2013 - search.ebscohost.com
The article presents a review of the stud regarding the effectiveness of teriflunomide and
interferon beta-1a in patients with relapsing multiple sclerosis (MS). It details the method of
the Phase III TENERE clinical trial which observes 7 milligrams (mg) teriflunomide, 14 mg
teriflunomide, and interferon-ß in patients with relapsing MS. It also outlines the findings of
the study which suggests that teriflunomide can be an effective alternative therapy for
patients with relapsing MS.
interferon beta-1a in patients with relapsing multiple sclerosis (MS). It details the method of
the Phase III TENERE clinical trial which observes 7 milligrams (mg) teriflunomide, 14 mg
teriflunomide, and interferon-ß in patients with relapsing MS. It also outlines the findings of
the study which suggests that teriflunomide can be an effective alternative therapy for
patients with relapsing MS.
以上显示的是最相近的搜索结果。 查看全部搜索结果